Rating Change
Stifel analysts initiated coverage on IDEAYA Biosciences, Inc. (NASDAQ:IDYA) with a rating of Buy on October 14, 2026.
new coverageNASDAQ:IDYA
Stifel Initiates Coverage on IDEAYA Biosciences, Inc. (IDYA) with Buy
Stifel analysts initiated coverage on IDEAYA Biosciences, Inc. (NASDAQ:IDYA) with a rating of Buy on October 14, 2026.
At publication ·
What changed
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) · new coverage
- Firm
- Stifel
- Rating
- Buy
- Price at event
- $33.83
- Market capitalization
- $2.9B
At a glance
Key takeaways
- Stifel initiated Buy coverage on IDEAYA Biosciences on October 14, 2026, with the stock trading at $33.83 and a market capitalization of $2.9 billion.
Market Context
IDEAYA Biosciences, Inc. operates in the Healthcare sector. The stock currently trades at $33.83 with a market capitalization of $2.9B. The stock has gained 30.6% over the past 52 weeks.
Analyst coverage from Stifel provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for IDEAYA Biosciences, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for IDEAYA Biosciences, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 14, 2026 | Stifel | Buy | N/A |
| Sep 09, 2026 | Guggenheim | Buy | N/A |
| Sep 01, 2026 | Citizens | Market Outperform | N/A |
| Aug 05, 2026 | Wedbush | Outperform | N/A |
| Aug 05, 2026 | Truist Securities | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View IDYA Stock Page
Frequently Asked Questions
What does the Buy rating mean for IDYA?
A rating of Buy from Stifel reflects the analyst's outlook on IDEAYA Biosciences, Inc. (NASDAQ:IDYA). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the IDYA forecast page.
